Interruption of the enterohepatic circulation of bile acids stimulates the esterification rate of cholesterol in human liver.
The activity of acyl CoA: cholesterol acyltransferase (ACAT), which catalyzes the esterification of cholesterol, was studied in liver microsomes obtained from cholestyramine-treated gallstone patients (n = 12) and patients with Crohn's disease who had undergone partial ileal resection (n = 11). Gallstone patients (n = 33) and gallstone-free subjects undergoing cholecystectomy because of polyps of the gallbladder (n = 8) served as controls. The mean levels of the ACAT activity were the same in the gallstone and the gallstone-free patient groups (6.0 +/- 0.4 and 6.1 +/- 1.1 pmol/min per mg protein, respectively). When exogenous cholesterol was added to the assay system the activities were increased four- to fivefold in both groups. The ACAT activity tended to be increased in the cholestyramine-treated patients (8.1 +/- 1.8 pmol/min per mg protein), and was significantly enhanced (P less than 0.005) in the ileal-resected patients (12.3 +/- 2.3 pmol/min per mg protein). When the enzyme activity was determined with added exogenous cholesterol, it was significantly higher compared to the controls in both the cholestyramine-treated patients and the patients with ileal resection (57.9 +/- 11.6 and 50.0 +/- 10.3 pmol/min per mg protein, respectively). The content of free and esterified cholesterol in liver homogenates and microsomes was not significantly different between the patient groups. We conclude that ACAT activity is increased in patients with interruption of the enterohepatic circulation of bile acids, and speculate that this reflects a stimulated uptake of lipoprotein cholesterol and may indicate that more cholesteryl esters are incorporated into very low density lipoproteins.
Ståhlberg
D
D
Department of Medicine, Karolinska Institutet, Huddinge Hospital, Sweden.
Reihnér
E
E
Angelin
B
B
Einarsson
K
K
D000328:Adult; D000368:Aged; D001647:Bile Acids and Salts / Q000378:metabolism*; D015500:Chloramphenicol O-Acetyltransferase / Q000378:metabolism; D002769:Cholelithiasis / Q000188:drug therapy / Q000378:metabolism; D002788:Cholesterol Esters / Q000378:metabolism*; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003424:Crohn Disease / Q000378:metabolism / Q000601:surgery; D004764:Enterohepatic Circulation / Q000502:physiology*; D005260:Female; D006801:Humans; D007082:Ileum / Q000601:surgery; D008099:Liver / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
D001647:Bile Acids and Salts; D002788:Cholesterol Esters; D002792:Cholestyramine Resin; D015500:Chloramphenicol O-Acetyltransferase